# Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

> **NCT01171989** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 391 (actual)

## Conditions studied

- Tetanus
- Diphtheria
- Haemophilus Influenzae Type b
- Hepatitis B
- Poliomyelitis
- Acellular Pertussis
- Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

## Interventions

- **BIOLOGICAL:** GSK2202083A vaccine
- **BIOLOGICAL:** Infanrix hexa™
- **BIOLOGICAL:** Menjugate™
- **BIOLOGICAL:** NeisVac-C™
- **BIOLOGICAL:** Synflorix™

## Key facts

- **NCT ID:** NCT01171989
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-18
- **Primary completion:** 2010-12-03
- **Final completion:** 2010-12-03
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2020-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01171989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01171989, "Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01171989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*